An al-Qaeda suspect was killed and another arrested in Pakistan, and authorities tried to determine on Thursday if the detained man is a Syrian who has a multimillion-dollar bounty on his head and once taught militants at Osama bin Laden's terror camps in Afghanistan.
Intelligence officials said a third man, linked to a Pakistani extremist group, was also captured in Tuesday's raid on a shop that was also the office of an Islamic charity linked to a hardline militant group.
The raid was in Quetta, capital of Pakistan's southwestern province of Baluchistan.
"I can only confirm that there was an encounter, and our security forces arrested one suspected al-Qaeda terrorist while another terrorist was killed," said Information Minister Sheikh Rashid Ahmed.
He said it would "take some time" to confirm their identities.
Authorities were investigating whether one of the suspects is Mustafa Setmarian Nasar, 47, a Syrian native who also holds Spanish citizenship, said a senior government official.
Intelligence officials said that the detained man has been "tightlipped and very uncooperative" during interrogations.
The US Justice Department has offered US$5 million for information leading to Nasar's arrest, describing him as an al-Qaeda member and former trainer at terrorist camps in Afghanistan who helped train extremists in using poisons and chemicals.
The department's Rewards for Justice Web site also says he is probably in Afghanistan or Pakistan.
Media reports have linked Nasar, also known as Abu Musab al-Suri, to the Mar. 11, 2004, Madrid bombings that left 191 people dead and more than 1,500 injured, and to this year's July 7 bombings in London that left 56 people dead, including the four bombers.
Police in Madrid said they have no confirmation that the suspect under arrest is Nasar. London's Metropolitan Police and the Home Office could not immediately comment on Britain's interest in Nasar.
Intelligence officials in Quetta said authorities got a tip that al-Qaeda members were visiting the shop, and decided to launch the raid on Tuesday.
Residents in Quetta's Sarki Road neighborhood said they saw Pakistani intelligence agents raiding the shop and dragging some men into a vehicle when gunshots rang out.
A witness, Mohammed Salahuddin, said some passers-by were hit, and one of the arrested men -- whose face had been covered with a black hood by the intelligence agents -- was bleeding.
"I was buying something when security officials suddenly entered the shop and overpowered two or three people. When they were throwing them in two vehicles, I heard gunshots and some passers-by fell down," Salahuddin said. "I don't know who opened the fire."
There was no official confirmation that any passers-by were injured in the raid.
An intelligence official in Quetta said the al-Qaeda suspect who died in the shootout was a Saudi named Sheikh Ali Mohammed al-Salim. The official said al-Salim had been living with Nasar.
He said the third man was a suspected member of Jaish-e-Mohammed, a Pakistani Islamic militant group allegedly linked to al-Qaeda.
US Embassy officials said they could not confirm the arrests.
Bari Dad, owner of the property where the raid took place, said he had rented the shop to a man he identified as Abdul Hanan. Dad said Hanan had also used it as an office for the Madina Trust, a Pakistani charity that is linked to Jaish-e-Mohammed.
Another resident, Nizam Din, said he believed Hanan -- apparently the third suspect mentioned by intelligence officials -- had links with Jaish-e-Mohammed, and helped recruit fighters for the wars in Afghanistan and Kashmir.
The COVID-19 variant discovered in South Africa can “break through” Pfizer-BioNTech’s COVID-19 vaccine to some extent, a real-world data study released on Saturday found, although its prevalence in the country is low and the research has not been peer reviewed. The study in Israel compared almost 400 people who had tested positive for COVID-19, 14 days or more after they received one or two doses of the vaccine, against the same number of unvaccinated people with the disease. It matched age and gender, among other characteristics. The South African variant, B.1.351, was found to make up about 1 percent of all the COVID-19
RARE ADMISSION: A top Chinese expert was the first to publicly address the efficacy of the nation’s vaccines as it aims to inoculate 40 percent of its population by June China is considering mixing different COVID-19 vaccines to improve the relatively low efficacy of its existing options, a top health expert told a conference in Chengdu on Saturday. Authorities have to “consider ways to solve the issue that efficacy rates of existing vaccines are not high,” Chinese media outlet The Paper reported, citing Chinese Center for Disease Control and Prevention Director Gao Fu (高福). His comments mark the first time a top Chinese expert has publicly alluded to the relatively low efficacy of the country’s vaccines, as China forges ahead in its mass vaccination campaign and exports its jabs around the world. China
The Australian government yesterday said that it had decided against buying the single-dose Johnson & Johnson (J&J) COVID-19 vaccine and identified a second case of a rare blood clot likely linked to the AstraZeneca shot. The Australian government had been in talks with the New Jersey-based pharmaceutical giant, which had asked the Australian Therapeutic Goods Administration for provisional registration. However, Australian Minister of Health Greg Hunt ruled out a J&J contract, because its vaccine was similar to the AstraZeneca product, which Australia had already contracted for 53.8 million doses. Hunt said the government was following the advice of Australia’s scientific and technical advisory
The Indonesian government has said it is satisfied with the effectiveness of the Chinese COVID-19 vaccine it has been using, after China’s top disease control official said that current vaccines offer low protection against the novel coronavirus. Siti Nadia Tarmizi, a spokesperson for Indonesia’s COVID-19 vaccine program, on Monday said the WHO had found that the Chinese vaccines had met requirements by being more than 50 percent effective. Clinical trials in Indonesia for the vaccine from Chinese drugmaker Sinovac showed that it was 65 percent effective, she said. “It means ... the ability to form antibodies in our bodies is still very